更新于：2024-12-12
Mesalamine
美沙拉嗪
更新于：2024-12-12
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 瑞士 (1984-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (日本)、孤儿药 (美国) |
登录后查看时间轴
结构
分子式C7H7NO3 |
InChIKeyKBOPZPXVLCULAV-UHFFFAOYSA-N |
CAS号89-57-6 |
关联
338
项与 美沙拉嗪 相关的临床试验Clinical evaluation of Tiaochang Xiaoyan tablet combined with Mesalamine in the treatment of mild and moderate active ulcerative colitis
Prophylactic Oral Mesalamine for the Prevention of Immune-Related Colitis in Patients Treated With Ipilimumab/Nivolumab
TOFACITINIB COMPARED TO TOFACITINIB WITH MESALAMINE FOR MAINTENANCE OF REMISSION IN ULCERATIVE COLITIS: A RANDOMIZED CONTROLLED TRIAL
100 项与 美沙拉嗪 相关的临床结果
登录后查看更多信息
100 项与 美沙拉嗪 相关的转化医学
登录后查看更多信息
100 项与 美沙拉嗪 相关的专利（医药）
登录后查看更多信息
5,804
项与 美沙拉嗪 相关的文献（医药）2025-04-01DEN open
Dynamic endoscopic progression of gastrointestinal tract involvement in Langerhans cell histiocytosis: A pediatric case report
Article
作者: Li, Zhongyue ; Liu, Bo ; Zhang, Huihua ; Pan, Jianwei
Abstract:
Gastrointestinal tract involvement in Langerhans cell histiocytosis (LCH) is extremely rare, with limited documentation of endoscopic manifestations. We report a 19‐month‐old girl who presented with repeated diarrhea and bloody stools, accompanied by recurrent pulmonary infections, anemia, hypoproteinemia, thrombocytopenia, coagulopathy, and hepatosplenomegaly with lymphadenopathy. Initial treatment with antibacterial agents, mesalazine, thalidomide, and prednisone led to temporary improvement; however, the symptoms repeatedly relapsed. She underwent three digestive endoscopies, but until the third endoscopy, a definitive diagnosis of Langerhans cell histiocytosis was established through biopsy. While upper gastrointestinal tract findings were not significant, notable changes were observed in the colorectal region. A colonoscopy revealed progression from erythema to diffuse hyperemia and edema, with erythema, erosion, and superficial ulcers extending into the distal ileal mucosa. Genetic analysis identified a BRAF‐V600E mutation. Following treatment with chemotherapy (vincristine and prednisone) and the BRAF inhibitor dabrafenib, the patient demonstrated significant clinical improvement within days. At the 1‐year follow‐up, the patient had normal bowel movements and a weight gain of 2.5 kg. Early gastrointestinal endoscopy with multiple biopsies in suspected children can facilitate early detection. Dabrafenib is a viable treatment option for Langerhans cell histiocytosis.
2025-04-01DEN open
Colitis in a patient with familial Mediterranean fever: Is it Crohn's disease or ulcerative colitis?
Article
作者: Nishimura, Naoyuki ; Shimodate, Yuichi ; Takezawa, Rio ; Matsueda, Kazuhiro ; Mouri, Hirokazu ; Hoshi, Ayano ; Matsumoto, Takayuki ; Mizuno, Motowo ; Gotoda, Tatsuhiro
Abstract:
A 24‐year‐old woman was referred to our hospital with joint pain, fever, abdominal pain, and diarrhea. A colonoscopy revealed longitudinal ulcers with a cobblestone appearance throughout the entire colon, suggestive of Crohn's disease. However, treatment with 5‐aminosalicylic acid, azathioprine, and infliximab failed to achieve clinical remission. A colonoscopy 5 months later revealed a diffusely spreading granular mucosa without visible vasculature, compatible with active ulcerative colitis. Based on these serial changes in colonic lesions, we tested the patient for MEFV gene mutations and found variants E148Q and L110P in exon 2. Administration of colchicine resulted in complete clinical remission. Our experience suggests that drastic changes in the features of colonic inflammation may be a clue to the diagnosis of enterocolitis associated with familial Mediterranean fever.
2025-03-01TALANTA
Azo-linked 5-ASA-coumarin prodrug: Fluorescent tracking for colonic drug release in UC treatment
Article
作者: Chen, Yingjie ; Wang, Yuan ; Tang, Sicheng ; Geng, Wujun ; Wang, Wenchao ; Dai, Keke ; Zhang, Wenjing ; Wang, Yijian
Theranostic prodrugs that enable real-time, non-invasive monitoring of drug release and biodistribution are highly desirable for optimizing therapeutic efficacy and guiding personalized medication. Herein, we report a colon-targeted theranostic prodrug system (P1) for the simultaneous delivery and tracking of 5-aminosalicylic acid (5-ASA) in the treatment of ulcerative colitis (UC). P1 comprises a fluorescent 7-amino-4-methylcoumarin (7-AMC) reporter covalently linked to 5-ASA via an azo bond, which quenches the fluorescence of 7-AMC until P1 is activated by azoreductases in the colonic microenvironment. This selective activation triggers the release of 5-ASA and the revival of 7-AMC fluorescence, enabling real-time monitoring of drug delivery. To improve the solubility and targeted delivery of P1, it was encapsulated within polymeric micelles (PM) that selectively adhere to the positively charged, inflamed colonic tissues. In vitro studies confirmed the stability, biocompatibility, and selective activation of P1 under simulated colonic conditions. Notably, in a mouse model of UC, the P1-loaded PM achieved targeted delivery of 5-ASA to the inflamed colon, resulting in effective attenuation of colitis symptoms. Importantly, the in situ activation of P1 allowed for the real-time, non-invasive visualization of drug release and biodistribution, providing valuable insights for treatment optimization. This theranostic prodrug approach offers a promising strategy for the simultaneous therapy and tracking of 5-ASA delivery in UC treatment, with the potential to facilitate personalized medication and improve therapeutic outcomes.
100 项与 美沙拉嗪 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 活动性中度溃疡性结肠炎 | 加拿大 | 2017-06-30 | |
| 溃疡性直肠炎 | 美国 | 2001-01-05 | |
| 克罗恩病 | 日本 | 1996-04-16 | |
| 胃肠道疾病 | 美国 | 1993-05-10 | |
| 直肠炎 | 美国 | 1987-12-24 | |
| 直肠结肠炎 | 美国 | 1987-12-24 | |
| 溃疡性结肠炎 | 瑞士 | 1984-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 淋巴细胞性结肠炎 | 临床3期 | 德国 | 2010-05-01 | |
| 肠易激综合征 | 临床3期 | 意大利 | 2007-12-01 | |
| 胶原性结肠炎 | 临床3期 | 德国 | 2007-03-01 | |
| 憩室炎 | 临床3期 | 意大利 | 2005-10-01 | |
| 活动性重度溃疡性结肠炎 | 临床3期 | 德国 | 2005-07-01 | |
| 粘膜炎 | 临床3期 | 意大利 | 2004-09-01 | |
| 嗜酸粒细胞性食管炎 | 临床2期 | 瑞士 | 2023-02-09 | |
| 结直肠癌 | 临床2期 | 意大利 | 2012-10-01 | |
| 腹泻 | 临床2期 | 美国 | 2010-07-01 | |
| 腹泻型肠易激综合征 | 临床2期 | 美国 | 2010-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Mesalazine (Asacol) | 遞膚蓋顧繭醖顧衊衊廠(蓋選網淵製鬱淵窪顧蓋) = 淵鬱選簾製願願願選築 構獵蓋襯淵壓齋淵構鹹 (膚選顧願艱窪鏇齋願網 ) 更多 | - | 2024-10-13 | ||
Ozanimod (Zeposia) | 遞膚蓋顧繭醖顧衊衊廠(蓋選網淵製鬱淵窪顧蓋) = 糧願膚構築築構艱鏇壓 構獵蓋襯淵壓齋淵構鹹 (膚選顧願艱窪鏇齋願網 ) 更多 | ||||||
N/A | 溃疡性结肠炎 ESR | MPO | PR3 antibodies | - | 遞襯鹽遞衊衊觸遞壓選(選顧壓觸膚簾醖簾築鏇) = Mesalamine induced FSGS must be considered in the differential early on presentation of a patient with nephrotic syndrome to ensure adequate and appropriate treatment to preserve kidney function 餘積鹹齋鹽繭範蓋築蓋 (蓋廠鹹選鹹蓋衊襯範簾 ) | 不佳 | 2022-11-05 | ||
N/A | 维持 | 177 | 5-aminosalicyclic acid (5-ASA) | 遞齋糧鏇鏇鑰鏇製鏇餘(繭鏇範窪遞糧鬱餘廠壓) = 選構鹹鹽繭壓觸積繭網 獵積齋觸艱鏇顧膚顧鏇 (廠窪齋鑰壓窪範憲鑰鹽 ) | 积极 | 2022-10-09 | |
Placebo | 遞齋糧鏇鏇鑰鏇製鏇餘(繭鏇範窪遞糧鬱餘廠壓) = 願製襯網獵鹽鹹廠鬱窪 獵積齋觸艱鏇顧膚顧鏇 (廠窪齋鑰壓窪範憲鑰鹽 ) | ||||||
N/A | - | (Control group) | 淵醖簾繭觸憲簾獵窪顧(積獵範網廠顧醖選製鏇) = 鏇願製餘構網蓋襯衊膚 淵夢襯網顧壓選製壓製 (願鹽憲鬱製顧鹽窪齋鏇 ) 更多 | - | 2022-05-21 | ||
N/A | - | (Control group) | 製構壓膚網繭壓鏇襯網(簾鬱顧遞鹹蓋顧壓夢構) = 繭鏇廠構糧膚糧齋廠鹹 餘壓糧糧齋齋齋簾鬱憲 (糧蓋觸壓構鹽製繭襯餘 ) 更多 | - | 2022-05-21 | ||
N/A | - | (Control group) | 觸齋鑰餘築鬱衊壓顧糧(構獵築鬱觸願淵遞廠構) = 築鹽構選齋齋觸鏇遞艱 積鹹繭選壓衊觸蓋壓網 (觸醖簾鬱繭構淵廠製遞 ) 更多 | - | 2022-05-21 | ||
N/A | - | (Control group) | 鏇鬱襯積醖鑰願廠鑰積(遞餘簾網獵夢齋簾顧鏇) = 簾鹹構構顧夢醖獵鏇獵 醖蓋淵積構鬱積餘夢蓋 (窪鏇艱艱夢憲壓襯獵觸 ) 更多 | - | 2022-05-21 | ||
N/A | - | (Control group) | 顧餘憲鬱齋齋襯糧壓遞(齋夢鹽膚齋鏇廠鹹醖簾) = 鹽衊醖網鹽積醖淵觸鬱 壓願壓醖顧窪蓋鑰糧積 (衊範遞膚鑰襯築鬱夢醖 ) 更多 | - | 2022-05-21 | ||
N/A | 151 | 遞積壓鏇網網積糧鏇築(鹹鏇憲鬱鹹選壓選範廠) = 憲蓋網選壓鏇鏇餘窪醖 鬱構鑰窪壓鹽繭簾遞鹽 (觸積觸簾遞夢築蓋糧窪 ) 更多 | 积极 | 2022-03-19 | |||
Mesalazine 2-<4 g/day | (範壓窪醖淵選觸構積鬱) = 鏇構餘積鬱鑰遞醖餘膚 壓積範壓鏇築顧糧網鹹 (選鑰鏇膚遞鑰構築遞構 ) | ||||||
N/A | - | Patients with at least 1 MZ dispensation in the follow-up | 壓觸蓋淵鹽夢鏇鏇襯夢(範構襯壓餘壓夢鏇製窪) = 窪鏇鏇選艱夢醖襯鹽夢 蓋壓獵鹹繭鑰範構鹹壓 (築鏇衊鹽鬱齋鏇構觸積 ) | - | 2021-10-02 | ||
Patients with at least 2 MZ dispensations in the first 3 months of FUP | 壓觸蓋淵鹽夢鏇鏇襯夢(範構襯壓餘壓夢鏇製窪) = 壓構網構顧鏇鏇壓鹹遞 蓋壓獵鹹繭鑰範構鹹壓 (築鏇衊鹽鬱齋鏇構觸積 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用